AbbVie to buy Stemcentrx in $5.8 bln deal
April 28, 2016 at 07:38 AM EDT
April 28 (Reuters) - Drugmaker AbbVie Inc said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.